Mortality Risk for Patients with Biopsy Gleason Grade Group 1 Prostate Cancer
Open Access
- 2 July 2024
- journal article
- research article
- Published by Elsevier in European Urology Oncology
- Vol. 7 (6) , 1520-1526
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Prostate Cancer Screening With PSA, Kallikrein Panel, and MRIJAMA, 2024
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2024
- Genomic classifiers and prognosis of localized prostate cancer: a systematic reviewProstate Cancer and Prostatic Diseases, 2024
- Grade and stage misclassification in intermediate unfavorable‐risk prostate cancer radiotherapy candidatesThe Prostate, 2022
- Salvage therapy for prostate cancer after radical prostatectomyNature Reviews Urology, 2021
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- MRI-Targeted or Standard Biopsy for Prostate-Cancer DiagnosisNew England Journal of Medicine, 2018
- Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate CancerJournal of Urology, 2015
- Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical ProstatectomyNew England Journal of Medicine, 2004
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999